Target (CBDY) Depreciation & Amortization (CF) (2017 - 2026)
Target (CBDY) reported Depreciation & Amortization (CF) of $229653.0 for Q1 2026, up 5.12% year-over-year from $218476.0 in Q1 2025, and up 1.91% quarter-over-quarter from $225338.0 in Q4 2025.
Target (CBDY) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Target (CBDY) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $229653.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $229653.0, up 5.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $909580.0 (up 1.21% YoY), and the FY2025 annual result was $898403.0, down 1.94% from the prior year.
- Depreciation & Amortization (CF) improved to $229653.0 in Q1 2026 per CBDY's latest filing, from $225338.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $269923.0 in Q4 2024 and troughed at $131606.0 in Q4 2023.
- A 5-year average of $220253.0 and a median of $227283.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 105.1% in 2024, then dropped 16.52% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $227624.0 in 2022, then tumbled by 42.18% to $131606.0 in 2023, then soared by 105.1% to $269923.0 in 2024, then dropped by 16.52% to $225338.0 in 2025, then increased by 1.91% to $229653.0 in 2026.
- Business Quant data shows CBDY's Depreciation & Amortization (CF) at $229653.0 in Q1 2026, $225338.0 in Q4 2025, and $227647.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Target | - | - | 191,787.00 | 229,653.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 229,653.00 |
| Mar 31, 2026 | 229,653.00 |
| Dec 31, 2025 | 225,338.00 |
| Dec 31, 2025 | 225,338.00 |
| Sep 30, 2025 | 227,647.00 |
| Sep 30, 2025 | 227,647.00 |
| Jun 30, 2025 | 226,942.00 |
| Jun 30, 2025 | 226,942.00 |
| Mar 31, 2025 | 218,476.00 |
| Mar 31, 2025 | 218,476.00 |
| Dec 31, 2024 | 269,923.00 |
| Dec 31, 2024 | 269,923.00 |
| Sep 30, 2024 | 206,628.00 |
| Sep 30, 2024 | 206,628.00 |
| Jun 30, 2024 | 203,691.00 |
| Jun 30, 2024 | 203,691.00 |
| Mar 31, 2024 | 235,971.00 |
| Mar 31, 2024 | 235,971.00 |
| Dec 31, 2023 | 131,606.00 |
| Dec 31, 2023 | 131,606.00 |